Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroscience ; 302: 47-58, 2015 Aug 27.
Article in English | MEDLINE | ID: mdl-25684748

ABSTRACT

Recent research suggests a complex role for microglia not only in Parkinson's disease but in other disorders involving alpha-synuclein aggregation, such as multiple system atrophy. In these neurodegenerative processes, the activation of microglia is a common pathological finding, which disturbs the homeostasis of the neuronal environment otherwise maintained, among others, by microglia. The term activation comprises any deviation from what otherwise is considered normal microglia status, including cellular abundance, morphology or protein expression. The microglial response during disease will sustain survival or otherwise promote cell degeneration. The novel concepts of alpha-synuclein being released and uptaken by neighboring cells, and their importance in disease progression, positions microglia as the main cell that can clear and handle alpha-synuclein efficiently. Microglia's behavior will therefore be a determinant on the disease's progression. For this reason we believe that the better understanding of microglia's response to alpha-synuclein pathological accumulation across brain areas and disease stages is essential to develop novel therapeutic tools for Parkinson's disease and other alpha-synucleinopathies. In this review we will revise the most recent findings and developments with regard to alpha-synuclein and microglia in Parkinson's disease.


Subject(s)
Brain/pathology , Microglia/metabolism , Parkinson Disease/pathology , alpha-Synuclein/metabolism , Animals , Gene Expression Regulation , Humans , Interleukin-1beta/metabolism , Parkinson Disease/metabolism , Tumor Necrosis Factor-alpha/metabolism
2.
Neuroscience ; 208: 85-96, 2012 Apr 19.
Article in English | MEDLINE | ID: mdl-22342967

ABSTRACT

We have previously shown that persistent α-synuclein overexpression in ventral midbrain of marmoset leads to a distinctive neurodegenerative process and motor defects. The neurodegeneration was confined to caudate putamen dopaminergic fibers in animals overexpressing wild-type (wt) α-synuclein. However, A53T α-synuclein overexpression induced neurodegeneration that resulted in nigral dopaminergic cell death. Here, we analyze the microglia population in the midbrain of these animals by stereological quantification of Iba1+ cells. Our data here show that monkeys overexpressing A53T α-synuclein showed a long-term increase in microglia presenting macrophagic morphology. However, wt α-synuclein overexpression, despite the absence of dopaminergic cell death, resulted in a permanent robust increase of the microglia population characterized by a range of distinct morphological types that persisted after 1 year. These results confirm that the microglial response differs depending on the type of α-synuclein (wt/A53T) and/or whether α-synuclein expression results in cell death or not, suggesting that microglia may play different roles during disease progression. Furthermore, the microglial response is modulated by events related to α-synuclein expression in substantia nigra and persists in the long term. The data presented here is in agreement with that previously observed in a recombinant adeno-associated virus (rAAV) α-synuclein rat model, thereby validating both the findings and the model, and highlighting the translational potential of the rodent model to higher species closer to humans.


Subject(s)
Cell Polarity/drug effects , Microglia/physiology , alpha-Synuclein/physiology , Animals , Callithrix , Caudate Nucleus/cytology , Caudate Nucleus/drug effects , Caudate Nucleus/physiology , Cell Count , Cell Death/drug effects , Dependovirus/genetics , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/physiology , Female , Genetic Vectors , Gliosis/chemically induced , Gliosis/pathology , HLA-DR Antigens/biosynthesis , Immunohistochemistry , Macrophage Activation/drug effects , Male , Mesencephalon/cytology , Mesencephalon/drug effects , Mutation/physiology , Neurodegenerative Diseases/pathology , Parkinson Disease, Secondary/pathology , Pluripotent Stem Cells/drug effects , Presynaptic Terminals/drug effects , Putamen/cytology , Putamen/drug effects , Putamen/physiology , alpha-Synuclein/biosynthesis , alpha-Synuclein/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...